MORGAN STANLEY PLC/PUT/MADRIGAL PHARMACEUTICALS/250/0.02/20.09.24

MORGAN STANLEY PLC/PUT/MADRIGAL PHARMACEUTICALS/250/0.02/20.09.24 Stock

DE000ME9GBG2

Real-time Bid/Ask 12:32:31 2024-07-16 EDT
0.31 ^EUR / 0.41 ^EUR	+16.13%

Current month	-6.06%
1 month	-20.51%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart MADRIGAL PHARMACEUTICALS, INC.

Chart MORGAN STANLEY PLC/PUT/MADRIGAL PHARMACEUTICALS/250/0.02/20.09.24

Latest news about MADRIGAL PHARMACEUTICALS, INC.

JMP Securities Raises Price Target on Madrigal Pharmaceuticals to $385 From $381, Maintains Market Outperform Rating	11:17am	MT
Non Alcoholic Fatty Liver Disease Pipeline 2024 \| Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceutical	07-10	AQ
Cantor Fitzgerald Starts Madrigal Pharmaceuticals With Neutral Rating	06-28	MT
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	06-11

More news

Quotes 5-day view

Date	Price	Change
24-07-16	0.32	+3.23%
24-07-15	0.31	+14.81%
24-07-12	0.27	+3.85%
24-07-11	0.26	-3.70%
24-07-10	0.27	+8.00%

Delayed Quote Börse Stuttgart

Last update July 16, 2024 at 11:30 am

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	MADRIGAL PHARMACEUTICALS, INC.
Issuer	Morgan Stanley
WKN	ME9GBG
ISIN	DE000ME9GBG2
Date issued	2024-03-01
Strike	250 $
Maturity	2024-09-20 (66 Days)
Parity	50 : 1
Emission price	1.05 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	1.25 €
Lowest since issue	0.23 €
Delta	-0.3x
Omega	4.259
Premium	16.99x
Gearing	14.17x
Moneyness	0.9007
Difference Strike	-28.83 $
Difference Strike %	-11.53%
Spread	0.1 €
Spread %	24.39%
Theoretical value	0.3650
Implied Volatility	73.19 %
Total Loss Probability	58.03 %
Intrinsic value	0.000000
Present value	0.3650
Break even	230.14 €
Theta	-0.03x
Vega	0.01x
Rho	-0x

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-Î² (THR-Î²) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Sector

More about the company

Consensus: Madrigal Pharmaceuticals, Inc.

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

280 USD

Average target price

365.3 USD

Spread / Average Target

+30.50%

Consensus